Anupam Goel1, Benjamin Littenberg, Robert C Burack. 1. Department of Internal Medicine, Division of General Internal Medicine, Wayne State University, UHC, Suite 5C, 4201 St. Antoine, Detroit, MI 48201, USA. agoel@med.wayne.edu
Abstract
BACKGROUND: While screening has been demonstrated to reduce breast cancer mortality, the optimal screening interval is unknown. We designed a study to determine the risk of an advanced breast cancer diagnosis by varying the interval between mammograms. METHODS: We reviewed a single state's mammography records of women diagnosed with breast cancer between 1994 and 2002. The pre-diagnosis screening interval was the number of days between the last two eligible mammograms preceding a cancer diagnosis. The interval was classified as annual (0.75-1.49 years), biennial (1.5-2.49 years) or longer (exceeding 2.49 years). Advanced breast cancer was >or=stage IIB, tumor size >2 cm, or >or=one lymph node with cancer. RESULTS: The probability of an advanced breast cancer diagnosis did not differ between women with an annual pre-diagnosis screening interval and women with a biennial interval (21.1% vs. 23.7%, P=0.262). A longer pre-diagnosis screening interval was weakly associated with advanced breast cancer (21.8% for intervals 0.75-2.49 years vs. 26.8% for longer intervals, P=0.070). In multivariate analysis, we found an interaction between the pre-diagnosis screening interval and age. Among women 50 years or older, the risk of an advanced breast cancer diagnosis risk was higher for women with a pre-diagnosis screening interval exceeding 2.49 years compared to women with shorter screening intervals (OR 1.99 [1.02-3.90]). CONCLUSIONS: We found no difference in advanced breast cancer rates between women using mammography annually or biennially. Among women 50 years or older, the advanced breast cancer rate increased when the pre-diagnosis screening interval exceeded 2.49 years.
BACKGROUND: While screening has been demonstrated to reduce breast cancer mortality, the optimal screening interval is unknown. We designed a study to determine the risk of an advanced breast cancer diagnosis by varying the interval between mammograms. METHODS: We reviewed a single state's mammography records of women diagnosed with breast cancer between 1994 and 2002. The pre-diagnosis screening interval was the number of days between the last two eligible mammograms preceding a cancer diagnosis. The interval was classified as annual (0.75-1.49 years), biennial (1.5-2.49 years) or longer (exceeding 2.49 years). Advanced breast cancer was >or=stage IIB, tumor size >2 cm, or >or=one lymph node with cancer. RESULTS: The probability of an advanced breast cancer diagnosis did not differ between women with an annual pre-diagnosis screening interval and women with a biennial interval (21.1% vs. 23.7%, P=0.262). A longer pre-diagnosis screening interval was weakly associated with advanced breast cancer (21.8% for intervals 0.75-2.49 years vs. 26.8% for longer intervals, P=0.070). In multivariate analysis, we found an interaction between the pre-diagnosis screening interval and age. Among women 50 years or older, the risk of an advanced breast cancer diagnosis risk was higher for women with a pre-diagnosis screening interval exceeding 2.49 years compared to women with shorter screening intervals (OR 1.99 [1.02-3.90]). CONCLUSIONS: We found no difference in advanced breast cancer rates between women using mammography annually or biennially. Among women 50 years or older, the advanced breast cancer rate increased when the pre-diagnosis screening interval exceeded 2.49 years.
Authors: Robert A Smith; Debbie Saslow; Kimberly Andrews Sawyer; Wylie Burke; Mary E Costanza; W Phil Evans; Roger S Foster; Edward Hendrick; Harmon J Eyre; Steven Sener Journal: CA Cancer J Clin Date: 2003 May-Jun Impact factor: 508.702
Authors: Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer Journal: N Engl J Med Date: 2005-10-27 Impact factor: 91.245
Authors: Wendy A Woodward; Eric A Strom; Susan L Tucker; Marsha D McNeese; George H Perkins; Naomi R Schechter; S Eva Singletary; Richard L Theriault; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: Michael S Simon; Sylvia Wassertheil-Smoller; Cynthia A Thomson; Roberta M Ray; F Allan Hubbell; Lawrence Lessin; Dorothy S Lane; Lew H Kuller Journal: Breast Cancer Res Treat Date: 2014-09-25 Impact factor: 4.872
Authors: Diana L Miglioretti; Weiwei Zhu; Karla Kerlikowske; Brian L Sprague; Tracy Onega; Diana S M Buist; Louise M Henderson; Robert A Smith Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Joost Nederend; Lucien Em Duijm; Adri C Voogd; Johanna H Groenewoud; Frits H Jansen; Marieke Wj Louwman Journal: Breast Cancer Res Date: 2012-01-09 Impact factor: 6.466
Authors: Carlos Canelo-Aybar; Margarita Posso; Nadia Montero; Ivan Solà; Zuleika Saz-Parkinson; Stephen W Duffy; Markus Follmann; Axel Gräwingholt; Paolo Giorgi Rossi; Pablo Alonso-Coello Journal: Br J Cancer Date: 2021-11-26 Impact factor: 9.075